U.S. and World News : Medical : Devices and Research News

Reaction Biology Corp. Awarded NIH R01 Screening Roadmap Grant for Microarray Screening Development

Mon, 13 Mar 2006, 21:06:00 EDT

Edited by Christopher Laird Simmons

MALVERN, PA (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ("RBC") today announced that it has been awarded an R01 grant from the National Institutes of Health to accelerate development of its new DiscoveryDot(TM) High Throughput Screening technology for drug discovery. The NIH grant is part of the Screening Roadmap, designed to produce innovative chemical tools for use in biological research and drug development. Out of 8 recipients of grants pursuant to the original RFA, Reaction Biology is the only private corporation to be so awarded.

The grant provides for $1,828,000 in funding over four years. It originates from the National Human Genome Research Institute and funds two specific areas: 1) The further development of RBC's proprietary spray deposition technology for High Throughput Screening ("HTS") reaction activation, and 2) The development of enhanced microarray printing technology for use in RBC's DiscoveryDot(TM) HTS system and elsewhere.

The DiscoveryDot(TM) technology currently is capable of screening up to 6,600 individual reactions at 1 nanoliter volume on a 1-by-3 inch glass slide. Millions of dollars can be saved on large scale screening campaigns through reagent savings, process costs, and labor reduction. RBC intends to further increase the throughput of its HTS process through the development of enhanced microarray printing and automated spray deposition.


About Reaction Biology Corporation

Reaction Biology, based in Malvern, Pa., provides high throughput screening services to the biotechnology and pharmaceutical industries. The company uses a patent-pending combination of technologies to perform screening at the nanoliter scale, while preserving quality, speed and simplicity.

Combining genomics microarray printing technology and picoliter aerosol deposition, RBC has commercialized a novel technology that drives HTS to new levels of simplicity and efficiency.

More information: http://www.reactionbiology.com

Reaction Biology Corporation, 1764 Litchfield Turnpike, Suite 203 * Woodbridge, CT 06525 * 203-389-7407.

R E A D E R   R E S O U R C E S
» E-mail This Article    » Printer-Friendly Version
» Choose RSS News Feeds by Topic
 Subscribe in a reader

Bookmark and/or share this content with your social network:
           

» Permalink for This Article
[ http://www.send2press.com/newswire/2006-03-0313-005.shtml ]

ADDITIONAL NEWS FROM Reaction Biology Corporation

» Reaction Biology Corp. Awarded NIH SBIR Grant for Kinase Radioisotope Microarray Screening Development » Key Organics Ltd and Reaction Biology Corporation Announce New Library Screening Format » Reaction Biology Corp. Awarded NIH R01 Screening Roadmap Grant for Microarray Screening Development » Reaction Biology Corporation and Key Organics Ltd Announce Drug Discovery Collaboration » Reaction Biology Corp. Awarded Phase II SBIR Grant for Drug Discovery

» More Devices and Research News  » Top of Page  » Home

J O U R N A L I S T   R E S O U R C E S

Media Copy of Original Press Release:
  PLAIN TEXT FORMAT (UTF-8)        PDF FORMAT

» Weekly E-Mail News Summary    » RSS Feeds by Topic
» Add Our Headlines to Your Site Automatically (FREE)

Find More News Content About
Reaction Biology Corporation

Site Search:  Our WebsiteCurrent NewsNews (pre-2005)Services